Molecular Modeling Study on Tunnel Behavior in Different Histone Deacetylase Isoforms

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Thangapandian, Sundarapandian ^a   John, Shalini ^a   Lee, Yuno ^a   Arulalapperumal, Venkatesh ^a   Lee, Keun Woo ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 8; LEUCINE; METHIONINE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVE SITE; ENZYME ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR SIZE; STRUCTURAL HOMOLOGY; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; BINDING SITES; CATALYTIC DOMAIN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; ISOENZYMES; LIGANDS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

EID: 84870566170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049327     Document Type: Article

References (40)

1. Woodcock CL, (2006) Chromatin architecture. Curr Opin Struct Biol 16: 213-220.
2. Hodawadekar SC, Marmorstein R, (2007) Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26: 5528-5540.
3. Wu J, Grunstein M, (2000) 25 years after the nucleosome model: chromatin modifications. Trends Biochem Sci 25: 619-623.
4. Raghuram N, Carrero G, Stasevich TJ, McNally JG, Th'ng J, et al. (2010) Core histone hyperacetylation impacts cooperative behavior and high-affinity binding of histone H1 to chromatin. Biochemistry 49: 4420-4431.
5. Lamblin M, Dabbas B, Spingarn R, Mendoza-Sanchez R, Wang TT, (2010) et al. Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids. Bioorg Med Chem 18: 4119-4137.
6. Gregoretti L, Lee Y, Goodson HV, (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
7. Thangapandian S, John S, Sakkiah S, Lee KW, (2010) Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur J Med Chem 45: 4409-4417.
8. Wang D, (2009) Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem 9: 241-256.
9. Imai S, Johnson FB, Marciniak RA, McVey M, Park PU, et al. (2000) Sir2: an NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging. Cold Spring Harb Symp Quant Biol 65: 297-302.
10. Frye RA, (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273: 793-798.
11. Timmerman S, Lehrmann H, Popesskaya A, Harel-Bellan A, (2001) Histone acetylation and disease. Cell Mol Life Sci 58: 728-736.
12. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP, (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625.
13. Paris M, Porcelloni M, Binaschi M, Fattori D, (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51: 1505-1529.
14. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
15. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS, (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26: 397-413.
16. Xu WS, Parmigiani RB, Marks PA, (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
17. Estiu G, Greenberg E, Harrison CB, Kwiatkowski NP, Mazitschek R, et al. (2008) Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem 51: 2898-2906.
18. Estiu G, West N, Mazitschek R, Greenberg E, Bradner JE, et al. (2010) On the inhibition of histone deacetylase 8. Bioorg Med Chem 18: 4103-4110.
19. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, et al. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12: 1325-1334.
20. Vannini A, Volpari C, Filocamo G, Caroli Casavola E, Brunetti M, et al. (2004) Crystal structure of a eukaryotic Zn-Dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Nat Acad Sci USA 101: 15064-15069.
21. Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, et al. (2008) Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 283: 11355-11363.
22. Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, et al. (2008) Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural Zinc-binding domain. J Biol Chem 283: 26694-26704.
23. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
24. Vannini A, Volpari C, Gallinari P, Jones P, Mattu M, et al. (2007) Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep 8: 879-884.
25. Thangapandian S, John S, Sakkiah S, Lee KW, (2010) Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. J Mol Graph Model 29: 382-395.
26. Bhalla KN, (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993.
27. Tran AD, Marmo TP, Salam AA, Che S, Finkelstein E, et al. (2007) HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 120: 1469-1479.
28. Hildmann C, Wegener D, Riester D, Hempel R, Schober A, et al. (2006) Substrate an inhibitor specificity of class 1 and class 2 histone deacetylases. J Biotechnol 124: 258-270.
29. Park JH, Jung Y, Kim T, Kim S, Jong HS, et al. (2004) Class 1 histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 10: 5271-5281.
30. Wang DF, Helquist P, Wiech NL, Wiest O, (2005) Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 48: 6936-6947.
31. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. (2004) UniProt: the universal protein knowledgebase. Nucleic Acids Res 32: D115-D119.
32. McGinnis S, Madden TL, (2004) BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res 32: W20-W25.
33. Eswar N, Marti-Renom MA, Webb B, Madhusudhan MS, Eramian D, et al. (2007) Comparative protein structure modeling with MODELLER. Curr Protoc Protein Sci Chapter 2: Unit 2.9.
34. Sali A, (1995) Comparative protein modeling by satisfaction of spatial restraints. Mol Med Today 1: 270-277.
35. Laskowski RA, MacArthur MW, Moss D, Thornton JM, (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 26: 283-291.
36. Hooft RW, Vriend G, Sander C, Abola EE, (1996) Errors in protein structures. Nature 381: 272-272.
37. Wiederstein M, Sippl MJ, (2007) ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research 35: W407-W410.
38. Hess B, Kutzner C, Van Der Spoel D, Lindahl E, (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem theory Comput 4: 435-447.
39. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005) Gromacs: Fast, flexible, and free. J Comput Chem 26: 1701-1718.
40. Cheng F, Wang Q, Chen M, Quiocho FA, Ma J, (2008) Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands. Proteins 70: 1228-1234.